Stay updated on MK-3475 and Gemcitabine in NSCLC Clinical Trial

Sign up to get notified when there's something new on the MK-3475 and Gemcitabine in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the MK-3475 and Gemcitabine in NSCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:37:36.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update or modification in the study details related to patients with previously-treated advanced non-small cell lung cancer (NSCLC) receiving MK-3475 and Gemcitabine as part of a clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:32:32.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide a more detailed explanation, now titled 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' and includes examples such as a person's general health condition or prior treatments. Additionally, the 'Eligibility Criteria Description' has been expanded to specify inclusion and exclusion criteria for participants.
    Difference
    25%
    Check dated 2024-05-22T21:11:42.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:32:21.000Z thumbnail image

Stay in the know with updates to MK-3475 and Gemcitabine in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the MK-3475 and Gemcitabine in NSCLC Clinical Trial page.